新型大环内酯类药物A-56268（TE-031）与红霉素和克林霉素相比，对所选革兰氏阳性菌和革兰氏阴性菌的体外活性。
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
作者信息
Benson C A, Segreti J, Beaudette F E, Hines D W, Goodman L J, Kaplan R L, Trenholme G M
出版信息
Antimicrob Agents Chemother. 1987 Feb;31(2):328-30. doi: 10.1128/AAC.31.2.328.
Abstract
The in vitro activity of A-56268 was determined and compared with that of erythromycin and clindamycin against a limited spectrum of 401 gram-positive and gram-negative organisms. A-56268 was quite active against erythromycin-susceptible Staphylococcus aureus, Neisseria gonorrhoeae, Listeria monocytogenes, Streptococcus pneumoniae, Streptococcus pyogenes, and group B streptococci and was moderately active against Campylobacter fetus subsp. fetus. A-56268 was consistently bactericidal only for S. pneumoniae. The activity of A-56268 was comparable to that of erythromycin against most organisms tested.
摘要
测定了A - 56268对401株革兰氏阳性和革兰氏阴性菌的体外活性，并将其与红霉素和克林霉素进行了比较。A - 56268对红霉素敏感的金黄色葡萄球菌、淋病奈瑟菌、单核细胞增生李斯特菌、肺炎链球菌、化脓性链球菌和B组链球菌有较强活性，对胎儿弯曲菌胎儿亚种有中等活性。A - 56268仅对肺炎链球菌始终具有杀菌作用。A - 56268对大多数测试菌株的活性与红霉素相当。
相似文献
1
In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.新型大环内酯类药物A-56268（TE-031）与红霉素和克林霉素相比，对所选革兰氏阳性菌和革兰氏阴性菌的体外活性。
Antimicrob Agents Chemother. 1987 Feb;31(2):328-30. doi: 10.1128/AAC.31.2.328.
2
Comparative in vitro activity of A-56268 (TE-031) against gram-positive and gram-negative bacteria and Chlamydia trachomatis.A-56268（TE-031）对革兰氏阳性菌、革兰氏阴性菌及沙眼衣原体的体外活性比较
Eur J Clin Microbiol. 1987 Apr;6(2):173-8. doi: 10.1007/BF02018203.
3
Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.新型红霉素衍生物地红霉素对从癌症患者中分离出的革兰氏阳性菌的体外比较活性
Eur J Clin Microbiol Infect Dis. 1990 Jan;9(1):30-3. doi: 10.1007/BF01969529.
4
CEM-101 activity against Gram-positive organisms.CEM-101 对革兰氏阳性菌的活性。
Antimicrob Agents Chemother. 2010 May;54(5):2182-7. doi: 10.1128/AAC.01662-09. Epub 2010 Feb 22.
5
Comparative in-vitro activity of A-56268 (TE-031), a new macrolide antibiotic.新型大环内酯类抗生素A-56268（TE-031）的体外活性比较
J Antimicrob Chemother. 1987 Nov;20(5):671-5. doi: 10.1093/jac/20.5.671.
6
7
8
Inducible clindamycin resistance in β-hemolytic streptococci and Streptococcus pneumoniae.β溶血性链球菌和肺炎链球菌中可诱导的克林霉素耐药性。
Isr Med Assoc J. 2013 Jan;15(1):27-30.
9
Antibacterial activity of rokitamycin compared with that of other macrolides.与其他大环内酯类药物相比，罗他霉素的抗菌活性
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):331-5. doi: 10.1016/0732-8893(91)90024-a.
10
Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides.新型11-O-氨基甲酰基克拉霉素酮内酯的合成与抗菌评价
Bioorg Med Chem Lett. 2017 Aug 15;27(16):3693-3697. doi: 10.1016/j.bmcl.2017.07.017. Epub 2017 Jul 5.
引用本文的文献
1
Choosing the right macrolide antibiotic. A guide to selection.选择合适的大环内酯类抗生素。选择指南。
Drugs. 1997 Mar;53(3):349-57. doi: 10.2165/00003495-199753030-00002.
2
Clarithromycin clinical pharmacokinetics.克拉霉素的临床药代动力学。
Clin Pharmacokinet. 1993 Sep;25(3):189-204. doi: 10.2165/00003088-199325030-00003.
3
Antimicrobial susceptibility of coagulase-negative staphylococci.凝固酶阴性葡萄球菌的抗菌药敏性
Antimicrob Agents Chemother. 1994 Oct;38(10):2231-7. doi: 10.1128/AAC.38.10.2231.
4
New directions for macrolide antibiotics: structural modifications and in vitro activity.大环内酯类抗生素的新方向：结构修饰与体外活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1413-8. doi: 10.1128/AAC.33.9.1413.
5
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms.阿奇霉素（CP - 62,993）的抗菌谱及作用方式，一种对革兰氏阴性菌效力增强的新型15元环大环内酯类抗生素。
Antimicrob Agents Chemother. 1987 Dec;31(12):1939-47. doi: 10.1128/AAC.31.12.1939.
6
In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.托氟沙星（A-60969）和克拉霉素（A-56268，TE-031）对耐药流感嗜血杆菌、肺炎链球菌和卡他莫拉菌分离株的体外活性。
Eur J Clin Microbiol Infect Dis. 1990 May;9(5):361-5. doi: 10.1007/BF01973747.
7
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.阿奇霉素、克拉霉素、红霉素和洛美沙星对肺炎支原体、人型支原体和解脲脲原体的体外活性比较
Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388.
8
In vitro susceptibilities of aerotolerant Campylobacter isolates to 22 antimicrobial agents.耐氧弯曲杆菌分离株对22种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 1992 Apr;36(4):717-22. doi: 10.1128/AAC.36.4.717.
9
Comparative in vitro activity of clarithromycin. Spanish Collaborative Group.克拉霉素的体外活性比较。西班牙协作组。
Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):856-66. doi: 10.1007/BF01960892.
10
Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.克拉霉素：抗菌活性、药代动力学特性及治疗潜力综述
Drugs. 1992 Jul;44(1):117-64. doi: 10.2165/00003495-199244010-00009.
本文引用的文献
1
Susceptibility of Legionella pneumophila to twenty antimicrobial agents.嗜肺军团菌对二十种抗菌药物的敏感性
Antimicrob Agents Chemother. 1980 Sep;18(3):403-8. doi: 10.1128/AAC.18.3.403.
2
Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.肺炎支原体对21种抗生素的体外敏感性
Am J Med Sci. 1967 Jun;253(6):639-50. doi: 10.1097/00000441-196706000-00001.
3
Comparative in vitro activities of twelve antimicrobial agents against Campylobacter species.十二种抗菌剂对弯曲杆菌属细菌的体外活性比较
Antimicrob Agents Chemother. 1985 Mar;27(3):429-30. doi: 10.1128/AAC.27.3.429.
4
Antimicrobial activity of several antibiotics and a sulfonamide against Chlamydia trachomatis organisms in cell culture.几种抗生素及一种磺胺类药物在细胞培养中对沙眼衣原体的抗菌活性。
Antimicrob Agents Chemother. 1977 Jul;12(1):80-3. doi: 10.1128/AAC.12.1.80.
5
Erythromycin: clinical review. II. Therapeutic uses.
N Y State J Med. 1977 Dec;77(14):2243-6.
6
Erythromycin: clinical review I. Clinical pharmacology.
N Y State J Med. 1977 Nov;77(13):2088-94.
Zotero 插件